Cargando…
Augmented Therapeutic Potential of Glutaminase Inhibitor CB839 in Glioblastoma Stem Cells Using Gold Nanoparticle Delivery
Gold nanoparticles (Au NPs) are studied as delivery systems to enhance the effect of the glutaminase1 inhibitor CB839, a promising drug candidate already in clinical trials for tumor treatments. Au NPs were synthesized using a bottom-up approach and covered with polymers able to bind CB839 as a Au-p...
Autores principales: | Giesen, Beatriz, Nickel, Ann-Christin, Barthel, Juri, Kahlert, Ulf Dietrich, Janiak, Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926460/ https://www.ncbi.nlm.nih.gov/pubmed/33672398 http://dx.doi.org/10.3390/pharmaceutics13020295 |
Ejemplares similares
-
CD133-Functionalized Gold Nanoparticles as a Carrier Platform for Telaglenastat (CB-839) against Tumor Stem Cells
por: Poonaki, Elham, et al.
Publicado: (2022) -
Metabolic Adjustments following Glutaminase Inhibition by CB-839 in Glioblastoma Cell Lines
por: De los Santos-Jiménez, Juan, et al.
Publicado: (2023) -
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells
por: Thompson, Ravyn M., et al.
Publicado: (2017) -
Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia
por: Timofeeva, Natalia, et al.
Publicado: (2023) -
DDRE-01. METABOLIC PLASTICITY AND HETEROGENEITY IN IDH1MUT CELL LINES PRODUCES RESISTANCE TO GLUTAMINASE INHIBITION BY CB839
por: Larion, Mioara, et al.
Publicado: (2021)